Febrile neutropenia is a common complication in cancer patients and has been studied for more than 30 years. This is a field of cancer in which much progress in supportive care has been made, significantly reducing the morbidity and mortality from infections. Tremendous numbers of patients have already benefited from specific antineoplastic therapy and an even greater number could benefit from the prevention of infection or from the allevation of symptoms as a result of effective prophylaxis or adequate therapeutic strategies. This book evaluates the achievements in the past and identifies the major existing problems. It gives an overview of therapeutic possibilities and presents new concepts and strategies for making further progress.

High-Dose Chemotherapy: Safer and Better?

Bone Marow Protectors in Cancer Treatment
Hematopoietic growth factors in febrile neutropenia - Indications and limitations
Incorporation of Quality-of-Life Considerations into Decisions Model for the Use of Colony-Stimulating Factors in Chemotherapy Patients at Risk for Febrile Neutropenia
Assessing Risk in Cancer Patients with Fever and Neutropenia
Therapeutic Approach in the Ambulatory Setting, Feasability and Surveillance
The Sequence of Infective Events in Prolonged Neutropenia
The Empirical Therapeutic Cascade: When to Start and When to Stop?
Treatment of Neutropenic Infection: Trends Towards Monotherapy?
The Changing Spectrum of Bacterial Infections in Febrile Neutropenic Patients
Susceptibility of Streptococci Isolated from Blood of Neutropenic Patients to 11 Antibiotics
Emerging Antibiotic Resistance in bacterial Pathogens
Cefepime Versus Ceftazidime as Empiric Therapy of Febrile Episodes in Neutropenic Patients
Cefepime Versus Ceftazidime in the Empiric Treatment of Febrile Neutropenic Children with Malignancy
Cefepime-Vancomycin Versus Ceftazidime-Vancomycin as Empiric Therapy in Febrile Neutropenic Patients
Monotherapy with Meropenem Versus Combination Therapy with Ceftazidime Plus Amikacin as Empiric Therapy for Fever in Granulocytopenic Patients with Cancer
Piperacillin plus Tazobactam Versus Ceftazidime plus Amikacin in Febrile Neutropenia: A Comparison in Terms of Cost and Efficacy
Fungal Infection in Neutropenic Patients: Past Achivements and Future Problems
The Pressure of Emerging Resistance in Fungal Diseases
Liposomal Versus Conventional Amphotericin B for the Treatment of Fever of Unknown Origin in Neutropenic Patients: Results of two Randomized Trials in 204 Childrenand 134 Adults
Pulmonary Infiltrate Etiology in Leukemic Patients with Fever
Marrow Transplantation: Current Results and Effect of Immunoglobulin Prophylaxis
The Role of Economic Evaluation in Assessing the Cost of Febrile Neutropenia
Quality of life in Patients with Febrile Neutropenia.